65 completed, 21 terminated, 18 recruiting, 12 active not recruiting. 135 Phase 2, 29 Phase 1, 3 Phase 3.
Follow Peripheral Nervous System Neoplasms: new trials by email Literature Review of Peripheral Nervous System Neoplasms trials Research Report on Peripheral Nervous System Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath Tumor avutometinib capsule + defactinib tablet - MPNST (Malignant Peripheral Nerve Sheath Tumor) | Phase 2 | Not yet recruiting | Girish Dhall, MD | 25 | 2027-01-01 | 2026-10-28 |
| Selumetinib for NF2-Related Schwannomatosis Selumetinib - Neurofibromatosis Type 2, NF2 | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 20 | 2026-12-01 | 2026-10-28 |
| Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas Selumetinib + ZEN-3694 ± Durvalumab - MPNST, NF1 | Phase 2 | Recruiting | University of Alabama at Birmingham | 41 | 2026-08-04 | 2026-08-24 |
| Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor BMS-986504 - Malignant Peripheral Nerve Sheath Tumors, MPNST | Phase 1 / Phase 2 | Recruiting | Ankit Mangla, MD | 17 | 2026-08-01 | 2026-08-11 |
| Luvometinib in Combination With Serplulimab for NF2-Related Tumors Luvometinib, Serplulimab - NF2-related Schwannomatosis, NF2 | Phase 1 / Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 30 | 2026-07-31 | 2026-07-16 |
| Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2) Selumetinib 25mg/m2, Luvometinib, Serplulimab - Neurofibromatosis Type 2, Vestibular Schwannoma | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 200 | 2026-07-18 | 2026-07-20 |
| Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST APG-115, Selumetinib - Malignant Peripheral Nerve Sheath Tumor (MPNST), Neurofibromatosis 1 (NF1) | Phase 1 / Phase 2 | Recruiting | AeRang Kim | 45 | 2026-06-01 | 2026-07-27 |
| Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors Miltenyi CliniMACS Prodigy ® system, Zoledronic acid - Neuroblastoma, Rhabdomyosarcoma | Phase 1 / Phase 2 | Recruiting | University of Florida | 27 | 2026-02-11 | 2026-06-30 |
| Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1 Selumetinib - Neurofibromatosis 1, Plexiform Neurofibroma | Phase 2 | Recruiting | University of Alabama at Birmingham | 200 | 2025-08-27 | 2026-05-29 |
| Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1 Luvometinib Tablets - Neurofibromatosis 1, Plexiform Neurofibroma | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 65 | 2025-06-12 | 2025-06-17 |
| Using CICS-1 and SPM-011 and [18F]FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA BNCT, [18F]FBPA - Thoracic Solid Malignant Tumor | Phase 1 / Phase 2 | Enrolling by invitation | Stella Pharma Corporation | 30 | 2025-04-10 | 2025-11-19 |
| IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS) Tislelizumab+liposomal doxorubicin+ifosfamide - Soft Tissue Sarcomas, Angiosarcoma | Phase 2 | Recruiting | Fudan University | 45 | 2025-02-25 | 2026-01-08 |
| A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1 HLX-1502 - Neurofibromatosis Type 1 | Phase 2 | Recruiting | Healx Limited | 25 | 2025-02-10 | 2026-07-29 |
| Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma AAVAnc80-antiVEGF via Akouos Delivery Device - Vestibular Schwannoma | Phase 1 / Phase 2 | Recruiting | Eli Lilly and Company | 27 | 2025-01-17 | 2026-11-04 |
| Low-dose Selumetinib for the Treatment of Plexiform Neurofibromas in Chinese Children Selumetinib - Plexiform Neurofibromas (PN) | Phase 2 | Not yet recruiting | West China Hospital | 50 | 2025-01-01 | 2025-01-08 |
| Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent RVP-001 - Central Nervous System (CNS) Lesions, Brain Metastases | Phase 2 | Completed | Reveal Pharmaceuticals Inc. | 18 | 2024-08-15 | 2025-12-26 |
| Phase II Study of FCN-159 in NF2 Nerve Sheath Tumors FCN-159 - Nerve Sheath Tumor | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 30 | 2024-08-15 | 2025-07-29 |
| Agnostic Therapy in Rare Solid Tumors Nivolumab - Urachal Cancer, Parathyroid Carcinoma | Phase 2 | Active not recruiting | Instituto do Cancer do Estado de São Paulo | 28 | 2024-07-16 | 2026-10-13 |
| NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) Surgical resection, Proton beam radiation therapy, Pazopanib - Adipocytic Neoplasm, Liposarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 139 | 2024-03-27 | 2026-08-03 |
| MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma MASCT-I, Doxorubicin, Ifosfamide - Leiomyosarcoma, Liposarcoma | Phase 2 | Recruiting | HRYZ Biotech Co. | 148 | 2024-02-21 | 2025-07-24 |
Showing 20 of 135. Sign in to see all of them.
Neurofibrosarcoma (57) · Sarcoma (45) · Neurofibromatosis 1 (33) · Leiomyosarcoma (30) · Sarcoma, Synovial (29) · Neurofibroma, Plexiform (28) · Histiocytoma, Malignant Fibrous (25) · Liposarcoma (24) · Fibrosarcoma (23) · Neuroma, Acoustic (22) · Hemangiosarcoma (21) · Optic Nerve Glioma (21) · Rhabdomyosarcoma (20) · Astrocytoma (19) · Sarcoma, Alveolar Soft Part (17)
Neoplasms by Histologic Type (135) · Nervous System Diseases (135) · Nervous System Neoplasms (135) · Neoplasms, Nerve Tissue (134) · Neoplasms (133) · Nerve Sheath Neoplasms (110) · Neurofibroma (99) · Neuromuscular Diseases (98) · Peripheral Nervous System Diseases (96) · Neoplasms, Connective and Soft Tissue (64) · Neoplasms by Site (62) · Neoplasms, Connective Tissue (62) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (59) · Neuroectodermal Tumors (59)
AZD 6244 (13) · Doxorubicin (10) · Imatinib Mesylate (6) · Bevacizumab (5) · Carboplatin (5) · Everolimus (5) · Ifosfamide (5) · Radiotherapy (5) · Temozolomide (5) · pazopanib (5) · Sirolimus (4) · Etoposide (3) · Vincristine (3) · pembrolizumab (3) · trametinib (3)
National Cancer Institute (NCI) (21) · European Organisation for Research and Treatment of Cancer - EORTC (7) · Memorial Sloan Kettering Cancer Center (6) · Sarcoma Alliance for Research through Collaboration (5) · University of Alabama at Birmingham (5) · Beijing Tiantan Hospital (4) · Novartis Pharmaceuticals (4) · Children's Oncology Group (3) · Duke University (3) · Assistance Publique - Hôpitaux de Paris (2) · City of Hope Medical Center (2) · Indiana University (2) · Maria Sklodowska-Curie National Research Institute of Oncology (2) · Mayo Clinic (2) · NYU Langone Health (2)
United States (91) · China (14) · Canada (13) · France (8) · Australia (6) · Netherlands (6) · Belgium (5) · Germany (5) · Puerto Rico (5) · United Kingdom (5) · Denmark (4) · New Zealand (4) · Switzerland (4) · Poland (3) · Spain (3)
Brigitte C Widemann, M.D. (4) · AeRang Kim, MD, PhD (3) · Henry S. Friedman, MD (3) · Brigitte C. Widemann, MD (2) · Brigitte Widemann, MD (2) · Chie-Schin Shih, MD (2) · Fu Zhao (2) · Pinan Liu (2) · William Tap, MD (2) · Aaron R Weiss (1) · Aaron Tward, MD (1) · Albert S Cornelius, MD (1) · Alexander Wei, MD (1) · Andrew Cluster, M.D. (1)
PMID 11705489, PMID 12528778, PMID 12957454, PMID 15010069, PMID 15177491, PMID 15592836, PMID 15659504, PMID 16408203, PMID 16528479, PMID 17095209, PMID 17336054, PMID 17610262, PMID 18989154, PMID 19088049, PMID 19451429, PMID 19451433, PMID 20381270, PMID 20471824, PMID 23382028, PMID 24215845, PMID 24500418, PMID 24753394, PMID 26976425, PMID 27502708, PMID 27510726, PMID 28029918, PMID 30284154, PMID 30339775, PMID 30410720, PMID 31401903, PMID 31881853, PMID 31969335, PMID 32089640, PMID 32187457, PMID 32562630, PMID 32702309, PMID 32827353, PMID 33362722, PMID 33442015, PMID 33507822, PMID 33536190, PMID 33882143, PMID 34321280, PMID 34331515, PMID 34380663, PMID 34515544, PMID 34716198, PMID 35007270, PMID 35229827, PMID 35467749
U10CA098543 (6), P30CA008748 (3), U10CA180886 (3), N01CM62206 (2), P30CA033572 (2), U10CA180821 (2), 2009 (1), 2017 (1), 2018 (1), N01CM17104 (1), N01CM62201 (1), N01CM62205 (1), P30CA006973 (1), P30CA012197 (1), P30CA013148 (1)